Health & Biotech
Incannex Healthcare Limited (IHL.ASX) is a clinical stage pharmaceutical development company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of Generalised Anxiety Disorder (GAD), Obstructive Sleep Apnoea (OSA), Traumatic Brain Injury (TBI)/Concussion, rheumatoid arthritis, inflammatory bowel disease and inflammatory lung conditions (ARDS, COPD, Asthma, Bronchitis).
FDA registration and marketing approval, subject to ongoing clinical success, is being pursued for each product and therapy under development.
Each indication represents major global markets and currently have either no, or limited, existing registered pharmacotherapy (drug) treatments available to the public, raising the possibility of patients receiving Government subsidies for products that demonstrate suitable safety and efficacy profiles in clinical trials.
Incannex has a strong patent filing strategy as it develops its products and therapies in conjunction with its medical and scientific advisory board and its collaborative partners, including Monash University and The Alfred Hospital.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
ASX health stocks: EMV’s brain scanner is completed and ready for testing, stock price jumps 16pc
News
Market Highlights and 5 ASX Small Caps to watch on Tuesday
Health & Biotech
A busy Q4 shows how Incannex Healthcare is laying the foundations for its clinically backed global growth strategy
Health & Biotech
Incannex kicks off Phase 1 clinical trial for its anti-inflammatory treatment
Health & Biotech
ASX health stocks: Proteomics jumps 10% on blood test deal with Nasdaq-listed Abcam
Health & Biotech
Incannex files global patent for its IHL-42X sleep apnoea treatment and receives ethics approval to administer to patients every day in an extension trial
Health & Biotech
ASX health stocks: AusCann (ASX:AC8) up 5pc after asking for approval of cannabis-based canine drug
Health & Biotech
Incannex secures complete supply chain solution for its anti-inflammatory multi-use drug
News
Market highlights and 5 ASX small caps to watch on Friday
Health & Biotech
Why this hidden gem in the Incannex product suite could be a global market winner
Health & Biotech
Global pharma leader Vectura will help Incannex develop its concussion treatment drug
News
Market highlights and 5 ASX small caps to watch on Monday
Health & Biotech
US growing approvals a ‘monumental’ step away from Trump moratorium on pot licensing
Health & Biotech
Incannex takes key step towards FDA approval for IHL-42X with new research partnership
News
Market highlights and 5 ASX small caps to watch on Tuesday
Health & Biotech
Incannex highlights Q1 momentum with 4C update, shares rally again
Health & Biotech